SAT0290 A Higher Disease Activity in Anti-Ssa/ssb Positive Sjögren's Syndrome Is Explained by A Higher Clinical and Biological B-Cell Activation: Table 1

Background Anti-SSA/SSB positive Sjogren9s syndrome is characterized by a higher risk for developing lymphoma (1), but no data already exist on systemic disease activity in subgroups of SS, as measured by validated scores for primary SS, such as the ESSDAI or ClinESSDAI. Objectives Primary objective of the study was to demonstrate the differences between anti-SSA/SSB positive and anti-SSA/SSB negative SS patients as regards systemic disease activity. Methods 955 patients affected by primary SS were included. All patients fulfilled the American-European Consensus Group Criteria for primary SS. Patients showing isolated anti-SSB positivity were excluded from these analyses. Patients were 911 female (95,4%), with a mean age of 52±14 years. ESSDAI and ClinESSDAI scores were measured (2, 3). Mann-Whitney U test was used to compare the ESSDAI and ClinESSDAI scores between anti-SSA/SSB positive and negative patients. Results Patients with anti-SSA with or without anti-SSB antibodies were 684 (71.6%), while anti-SSA and anti-SSB antibody negative patients were 271 (28.4%). Median (range) ESSDAI and median (range) ClinESSDAI were 5 (0–54) and 6 (0–53) in anti-SSA/SSB positive patients, and 4 (0–63) and 4 (0–60) in anti-SSA/SSB negative patients, respectively. Both the ESSDAI and the ClinESSDAI scores were significantly higher in anti-SSA/SSB positive patients (p Conclusions Clinical and biological signs of B-cell lymphoproliferation more specifically characterized anti-SSA/SSB positive patients, glandular, hematological and biological domains showing the most significant differences. This feature appears to clearly differentiate Sjogren9s disease from Sjogren9s syndrome. References Quartuccio L, et al. Autoimmun Rev. 2015;14:1019–22. Seror R, et al. Ann Rheum Dis 2010;69:1103–9. Seror R, et al. Ann Rheum Dis 2015;74:579 Disclosure of Interest None declared